BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:
Limitations of Use: BREYANZI is not indicated for the treatment of patients with primary central nervous system lymphoma.
Patients can receive a disposable wearable technology during the initial postinfusion monitoring period–they can then track their temperature in real time through their smartphone when outside the treatment center.
Patients are instructed to call their healthcare provider or go to the hospital if their temperature is 110.4°F/38.0°C or higher.
Additional eligibility requirements apply. Patients may enroll in support programs offered through Cell Therapy 360® after a certified CAR T cell therapy treatment center determines that Breyanzi is the right treatment for them.
If you have any additional questions about Breyanzi, please use the information provided below to contact a representative.
Call us at 1-800-321-1335.
This website is best viewed
using the horizontal display on
your tablet device.
This website is best viewed
using the vertical display on
your mobile device.